DIFFERENTIAL REGIONAL EFFECTS OF LONG-TERM L-DOPA TREATMENT ON PREPROENKEPHALIN AND PREPROTACHYKININ GENE-EXPRESSION IN THE STRIATUM OF 6-HYDROXYDOPAMINE-LESIONED RAT
P. Salin et al., DIFFERENTIAL REGIONAL EFFECTS OF LONG-TERM L-DOPA TREATMENT ON PREPROENKEPHALIN AND PREPROTACHYKININ GENE-EXPRESSION IN THE STRIATUM OF 6-HYDROXYDOPAMINE-LESIONED RAT, Molecular brain research, 47(1-2), 1997, pp. 311-321
The present study examined the effects of prolonged L-DOPA treatment (
6 months) alone or in combination with unilateral 6-hydroxydopamine-in
duced lesion of the mesostriatal dopaminergic pathway on substance P a
nd enkephalin mRNA expression in the rat neostriatum, This was done by
means of quantitative in situ hybridization histochemistry. As report
ed previously, the unilateral dopaminergic lesion induced a significan
t and homogeneous decrease in striatal substance P mRNA expression and
a marked increase in enkephalin mRNA expression in the ipsilateral ne
ostriatum which was more pronounced in the dorsolateral than ventromed
ial part of the structure. Long-term L-DOPA treatment alone had no sig
nificant effects on the two striatal peptide mRNA levels. The chronic
L-DOPA treatment in 6-hydroxydopamine-lesioned rats was found to parti
ally reverse the lesion-induced down-regulation of substance P mRNA ex
pression, without significantly affect the up-regulation of enkephalin
when considering the neostriatum as a whole. Topographical analysis r
evealed that long-term L-DOPA treatment reversed, in fact, both post-l
esional enkephalin and substance P responses to 6-hydroxydopamine lesi
on, in the ventromedial neostriatum, without significantly modified th
ese peptide responses in the dorsolateral neostriatum. These findings
provide new evidence that prolonged L-DOPA treatment differentially af
fects the post-lesional peptide responses in the ventromedial and dors
olateral parts of the neostriatum, suggesting regional cellular mechan
isms in the neostriatum underlying the benefit and/or side-effects of
L-DOPA treatment in parkinsonian patients. (C) 1997 Elsevier Science B
.V.